Harrow (HROW) Free Cash Flow Growth (5y) (2015 - 2026)
Harrow (HROW) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.95 Bn | 88.09 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.20 Bn | 1.97 Bn |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.35 Bn | 18.55 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.33% |
| Dec 31, 2025 | 70.61% |
| Sep 30, 2025 | 46.18% |
| Jun 30, 2025 | 23.78% |
| Mar 31, 2025 | 93.78% |
| Dec 31, 2024 | -93.08% |
| Sep 30, 2024 | 99.97% |
| Jun 30, 2024 | -49.59% |
| Mar 31, 2024 | -22.80% |
| Dec 31, 2023 | 68.42% |
| Sep 30, 2023 | -64.64% |
| Jun 30, 2023 | 37.49% |
| Mar 31, 2023 | -49.74% |
| Dec 31, 2022 | -57.21% |
| Sep 30, 2022 | 10.07% |
| Jun 30, 2022 | 30.99% |
| Mar 31, 2022 | 16.39% |
| Sep 30, 2021 | 31.36% |
| Jun 30, 2021 | 19.10% |
| Mar 31, 2021 | 21.45% |